J Exp Clin Cancer Res. 2018 Mar 5;37(1):47. doi: 10.1186/s13046-018-0702-x.
Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.
Allegretti M1,2, Fabi A2,3, Buglioni S2,4, Martayan A2,5, Conti L2,5,6, Pescarmona E2,4,6, Ciliberto G2,7, Giacomini P8,9.
Bioinformatics; Cancer screening and prevention; Ethics; Genomic aberrations; Next generation sequencing (NGS); Patient advocacy; Precision medicine; Regulatory issues
Free full text